Compare DAVA & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAVA | AVXL |
|---|---|---|
| Founded | 2000 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.2M | 115.9M |
| IPO Year | 2015 | 2013 |
| Metric | DAVA | AVXL |
|---|---|---|
| Price | $2.12 | $1.37 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $5.39 | N/A |
| AVG Volume (30 Days) | 563.2K | ★ 1.3M |
| Earning Date | 11-02-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.02 | N/A |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $1.14 |
| 52 Week High | $9.88 | $8.97 |
| Indicator | DAVA | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 47.90 | 27.14 |
| Support Level | $1.60 | N/A |
| Resistance Level | $3.06 | $1.60 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 74.12 | 32.59 |
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.